Core Viewpoint - InMed Pharmaceuticals has published a peer-reviewed study demonstrating the anti-inflammatory effects of cannabinol (CBN) through modulation of the endocannabinoid system, indicating its potential therapeutic applications for inflammatory skin diseases [2][4]. Company Overview - InMed Pharmaceuticals is focused on developing proprietary small molecule drug candidates targeting CB1/CB2 receptors, with a pipeline that includes programs for Alzheimer's disease, ocular conditions, and dermatological indications [6]. Study Findings - The study, conducted in collaboration with Dr. Mauro Maccarrone, found that CBN can prevent keratinocyte inflammation via TRPV1, express mitogen-activated protein kinases, modulate endocannabinoid-regulating enzymes, increase CB1 expression, and alter cytokine release by reducing pro-inflammatory cytokines (IL-8, IL-12, IL-31) while increasing the anti-inflammatory cytokine IL-10 [3][4]. - The anti-inflammatory activity of CBN suggests its potential to regulate epidermal functions and provide protective roles in the skin [4]. Expert Commentary - Dr. Mauro Maccarrone highlighted the significance of the study in providing scientific evidence for CBN's anti-inflammatory properties, supporting its therapeutic and cosmetic applications in treating inflammatory skin conditions [4]. - Dr. Eric Hsu emphasized the importance of understanding the endocannabinoid system in the context of various diseases and how rare cannabinoids may modulate inflammation [4].
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System